BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27291931)

  • 1. SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia.
    Deng A; Ning Q; Zhou L; Liang Y
    Sci Rep; 2016 Jun; 6():27694. PubMed ID: 27291931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Wang WD
    Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.
    Fu L; Shi J; Hu K; Wang J; Wang W; Ke X
    Oncotarget; 2015 Apr; 6(10):8144-54. PubMed ID: 25924238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations.
    Ryotokuji T; Yamaguchi H; Ueki T; Usuki K; Kurosawa S; Kobayashi Y; Kawata E; Tajika K; Gomi S; Kanda J; Kobayashi A; Omori I; Marumo A; Fujiwara Y; Yui S; Terada K; Fukunaga K; Hirakawa T; Arai K; Kitano T; Kosaka F; Tamai H; Nakayama K; Wakita S; Fukuda T; Inokuchi K
    Haematologica; 2016 Sep; 101(9):1074-81. PubMed ID: 27247325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia.
    Wang N; Guo D; Zhao YY; Dong CY; Liu XY; Yang BX; Wang SW; Wang L; Liu QG; Ren Q; Lin YM; Ma XT
    Oncotarget; 2015 Aug; 6(25):20977-92. PubMed ID: 26023795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
    Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
    J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects.
    Wellbrock J; Latuske E; Köhler J; Wagner K; Stamm H; Vettorazzi E; Vohwinkel G; Klokow M; Uibeleisen R; Ehm P; Riecken K; Loges S; Thol F; Schubert C; Amling M; Jücker M; Bokemeyer C; Heuser M; Krauter J; Fiedler W
    Clin Cancer Res; 2015 May; 21(10):2388-98. PubMed ID: 25745035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions.
    Fu L; Fu H; Wu Q; Pang Y; Xu K; Zhou L; Qiao J; Ke X; Xu K; Shi J
    J Transl Med; 2017 Jul; 15(1):159. PubMed ID: 28724426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
    Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
    Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of CPNE3 predicts adverse prognosis in acute myeloid leukemia.
    Fu L; Fu H; Qiao J; Pang Y; Xu K; Zhou L; Wu Q; Li Z; Ke X; Xu K; Shi J
    Cancer Sci; 2017 Sep; 108(9):1850-1857. PubMed ID: 28670859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SIRT2 mediates multidrug resistance in acute myelogenous leukemia cells via ERK1/2 signaling pathway.
    Xu H; Li Y; Chen L; Wang C; Wang Q; Zhang H; Lin Y; Li Q; Pang T
    Int J Oncol; 2016 Feb; 48(2):613-23. PubMed ID: 26647771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive DNA repair gene expression analysis and its prognostic significance in acute myeloid leukemia.
    Park S; Kim YJ; Huh HJ; Chung HS; Lee M; Park YM; Mun YC; Seong CM; Huh J
    Hematology; 2021 Dec; 26(1):904-913. PubMed ID: 34789078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Ang Q; Wang GJ; Zhu J; Wang WD
    Oncotarget; 2016 Jan; 7(3):2585-95. PubMed ID: 26506237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced expressions of FHL2 and iASPP predict poor prognosis in acute myeloid leukemia.
    Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Zhang Z; Qin T; Hu N; Zhang Y; Ke X; Chen Y; Wu D; Shi J; Fu L
    Cancer Gene Ther; 2019 Feb; 26(1-2):17-25. PubMed ID: 29910468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
    Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
    Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia.
    Fu L; Fu H; Tian L; Xu K; Hu K; Wang J; Wang J; Jing H; Shi J; Ke X
    Oncotarget; 2016 Mar; 7(13):15828-39. PubMed ID: 26910834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia.
    Zhang Q; Han Q; Zi J; Song C; Ge Z
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32400873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of
    Cui W; Liu Y; Tan Y; Peng X; Cui L; Cheng Z; Dai Y; Fu L; Zeng T; Liu Y
    Future Oncol; 2021 Feb; 17(5):541-548. PubMed ID: 33467898
    [No Abstract]   [Full Text] [Related]  

  • 20. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
    Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
    J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.